Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2017 Mar:51:178.e1-178.e9.
doi: 10.1016/j.neurobiolaging.2016.11.010. Epub 2016 Nov 24.

ATXN2 trinucleotide repeat length correlates with risk of ALS

William Sproviero  1 , Aleksey Shatunov  1 , Daniel Stahl  2 , Maryam Shoai  3 , Wouter van Rheenen  4 , Ashley R Jones  1 , Safa Al-Sarraj  5 , Peter M Andersen  6 , Nancy M Bonini  7 , Francesca L Conforti  8 , Philip Van Damme  9 , Hussein Daoud  10 , Maria Del Mar Amador  11 , Isabella Fogh  1 , Monica Forzan  12 , Ben Gaastra  1 , Cinzia Gellera  13 , Aaron D Gitler  14 , John Hardy  3 , Pietro Fratta  15 , Vincenzo La Bella  16 , Isabelle Le Ber  17 , Tim Van Langenhove  18 , Serena Lattante  19 , Yi-Chung Lee  20 , Andrea Malaspina  21 , Vincent Meininger  22 , Stéphanie Millecamps  19 , Richard Orrell  23 , Rosa Rademakers  24 , Wim Robberecht  25 , Guy Rouleau  10 , Owen A Ross  24 , Francois Salachas  26 , Katie Sidle  3 , Bradley N Smith  1 , Bing-Wen Soong  20 , Gianni Sorarù  27 , Giovanni Stevanin  28 , Edor Kabashi  19 , Claire Troakes  1 , Christine van Broeckhoven  29 , Jan H Veldink  4 , Leonard H van den Berg  4 , Christopher E Shaw  1 , John F Powell  1 , Ammar Al-Chalabi  30
Affiliations
Meta-Analysis

ATXN2 trinucleotide repeat length correlates with risk of ALS

William Sproviero et al. Neurobiol Aging. 2017 Mar.

Abstract

We investigated a CAG trinucleotide repeat expansion in the ATXN2 gene in amyotrophic lateral sclerosis (ALS). Two new case-control studies, a British dataset of 1474 ALS cases and 567 controls, and a Dutch dataset of 1328 ALS cases and 691 controls were analyzed. In addition, to increase power, we systematically searched PubMed for case-control studies published after 1 August 2010 that investigated the association between ATXN2 intermediate repeats and ALS. We conducted a meta-analysis of the new and existing studies for the relative risks of ATXN2 intermediate repeat alleles of between 24 and 34 CAG trinucleotide repeats and ALS. There was an overall increased risk of ALS for those carrying intermediate sized trinucleotide repeat alleles (odds ratio 3.06 [95% confidence interval 2.37-3.94]; p = 6 × 10-18), with an exponential relationship between repeat length and ALS risk for alleles of 29-32 repeats (R2 = 0.91, p = 0.0002). No relationship was seen for repeat length and age of onset or survival. In contrast to trinucleotide repeat diseases, intermediate ATXN2 trinucleotide repeat expansion in ALS does not predict age of onset but does predict disease risk.

Keywords: ALS; ATXN2; Age of onset; Amyotrophic lateral sclerosis; CAG; Expansion; Exponential risk; Intermediate expansion; Risk; SCA2; Trinucleotide repeat; Triplet.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Distribution of ATXN2 alleles with trinucleotide repeat size 24 or more in the (A) British and (B) Dutch datasets. (A) The British dataset included 1474 ALS individuals and 574 controls. There were 2867 alleles of size 23 or less in cases and 1105 in controls. (B) The Dutch dataset included 1328 ALS individuals and 691 controls. There were 2596 alleles of size 23 or less in cases and 1344 in controls.
Fig. 2
Fig. 2
Flow chart of study selection according to the PRISMA protocol. Thirteen previously published studies were selected for analysis, 7 from Europe (Conforti et al., 2012, Corrado et al., 2011, Daoud et al., 2011, Gispert et al., 2012, Lattante et al., 2014, Van Damme et al., 2011, Van Langenhove et al., 2012), 3 studies of Han Chinese (2 from China [Liu et al., 2013, Lu et al., 2015] and 1 from Taiwan [Soong et al., 2014]), 1 from Turkey (Lahut et al., 2012), and 2 studies from the USA (Elden et al., 2010, Ross et al., 2011).
Fig. 3
Fig. 3
Forest plots of individual alleles between 29 and 33 repeats. Primary analysis of the relative risk of ALS was conducted using low risk-bias case-control studies. UK = new UK data, NL = new Dutch data. Relative risk (RR) was estimated using a fixed effects approach and by comparing individual counts of ATXN2 alleles with the pooled count of alleles with ≤23 repeats as baseline. (A) ATXN2 allele of 29 repeats, RR = 1.68 (1.11, 2.54). No heterogeneity was observed (p-value of heterogeneity >0.05). (B) ATXN2 allele of 30 repeats, RR = 2.02 (1.30, 3.15). One of 15 studies was excluded for absence of carriers of allele 30, both in cases and controls. Significant heterogeneity was observed (p-value of heterogeneity <0.05). (C) ATXN2 allele of 31 repeats, RR = 2.96 (1.73, 5.05). One of 15 studies was excluded for absence of carriers of allele 31, both in cases and controls. No heterogeneity was observed (p-value of heterogeneity >0.05). (D) ATXN2 allele of 32 repeats, RR = 8.37 (4.02, 17.43). Two of 15 studies were excluded for absence of carriers of allele 32, both in cases and controls. No heterogeneity was observed (p-value of heterogeneity >0.05). (E) ATXN2 allele of 33 repeats, RR = 4.73 (1.92, 11.63). No heterogeneity was observed (p-value of heterogeneity >0.05). Abbreviation: ALS, amyotrophic lateral sclerosis.
Fig. 3
Fig. 3
Forest plots of individual alleles between 29 and 33 repeats. Primary analysis of the relative risk of ALS was conducted using low risk-bias case-control studies. UK = new UK data, NL = new Dutch data. Relative risk (RR) was estimated using a fixed effects approach and by comparing individual counts of ATXN2 alleles with the pooled count of alleles with ≤23 repeats as baseline. (A) ATXN2 allele of 29 repeats, RR = 1.68 (1.11, 2.54). No heterogeneity was observed (p-value of heterogeneity >0.05). (B) ATXN2 allele of 30 repeats, RR = 2.02 (1.30, 3.15). One of 15 studies was excluded for absence of carriers of allele 30, both in cases and controls. Significant heterogeneity was observed (p-value of heterogeneity <0.05). (C) ATXN2 allele of 31 repeats, RR = 2.96 (1.73, 5.05). One of 15 studies was excluded for absence of carriers of allele 31, both in cases and controls. No heterogeneity was observed (p-value of heterogeneity >0.05). (D) ATXN2 allele of 32 repeats, RR = 8.37 (4.02, 17.43). Two of 15 studies were excluded for absence of carriers of allele 32, both in cases and controls. No heterogeneity was observed (p-value of heterogeneity >0.05). (E) ATXN2 allele of 33 repeats, RR = 4.73 (1.92, 11.63). No heterogeneity was observed (p-value of heterogeneity >0.05). Abbreviation: ALS, amyotrophic lateral sclerosis.
Fig. 4
Fig. 4
Forest plot of the relative risk of ALS for ATXN2 alleles with 29–33 trinucleotide repeats. UK = new UK data, NL = new Dutch data. Fifteen studies at low risk of bias were included. Fixed effects methods were used to estimate the relative risk. No heterogeneity was observed (p-value of heterogeneity >0.05). Abbreviation: ALS, amyotrophic lateral sclerosis.
Fig. 5
Fig. 5
Plot of the relative risk for each ATXN2 allele (25–32 repeats). The distribution of the relative risk estimates of alleles of between 25 and 32 CAG trinucleotide repeats obtained from the 15 low bias studies fitted an exponential curve well, showing an exponential growth in relative risk, surpassing the threshold for significant association for alleles of size 29–32 (R2 = 0.91 [95% CI 0.82, 0.99], p = 0.0002). The relative risk estimate of the 24 repeat allele was excluded because of a large unidentified heterogeneity across studies. Including this allele, however, did not significantly change the curve fit. Black bars indicate the 95% CI of the relative risk estimates. The red line indicates no effect. Abbreviation: CI, confidence interval.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Abel O., Powell J.F., Andersen P.M., Al-Chalabi A. ALSoD: a user-friendly online bioinformatics tool for amyotrophic lateral sclerosis genetics. Hum. Mutat. 2012;33:1345–1351. - PubMed
    1. Al-Chalabi A., Calvo A., Chio A., Colville S., Ellis C.M., Hardiman O., Heverin M., Howard R.S., Huisman M.H., Keren N., Leigh P.N., Mazzini L., Mora G., Orrell R.W., Rooney J., Scott K.M., Scotton W.J., Seelen M., Shaw C.E., Sidle K.S., Swingler R., Tsuda M., Veldink J.H., Visser A.E., van den Berg L.H., Pearce N. Analysis of amyotrophic lateral sclerosis as a multistep process: a population-based modelling study. Lancet Neurol. 2014;13:1108–1113. - PMC - PubMed
    1. Al-Chalabi A., Hardiman O. The epidemiology of ALS: a conspiracy of genes, environmental and time. Nat. Rev. Neurol. 2013;9:617–628. - PubMed
    1. Burnham K.P., Anderson D.R. Springer-Verlag; New York: 2002. Model Selection and Multimodel Inference: A Practical Information-theoretic Approach.
    1. Chen Y., Huang R., Yang Y., Chen K., Song W., Pan P., Li J., Shang H.F. Ataxin-2 intermediate-length polyglutamine: a possible risk factor for Chinese patients with amyotrophic lateral sclerosis. Neurobiol. Aging. 2011;32:1925. - PubMed

Publication types